Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATV-1601 in Hereditary Hemorrhagic Telangiectasia
NCT07601425Phase 2Recruiting
- Sponsor
- Atavistik Bio
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ATV-1601 in hereditary hemorrhagic telangiectasia (HHT), sponsored by Atavistik Bio. Started Jul 2026; status: recruiting.
02
Drugs
ATV-1601
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT07601425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601425.